A Randomized, Open-Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-493 and ABT-530 in Adult Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Trial Profile

A Randomized, Open-Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-493 and ABT-530 in Adult Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2015

At a glance

  • Drugs Glecaprevir (Primary) ; Pibrentasvir (Primary) ; Dasabuvir; Ombitasvir/paritaprevir/ritonavir; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 10 Jun 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov record.
    • 23 Apr 2014 According to ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
    • 06 Mar 2014 According to ClinicalTrials.gov record, planned end date changed from 1 May 2015 to 1 Jun 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top